High dose pamidronate: Clinical and biochemical effects in metastatic bone disease

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1686-1690

  Coleman, Robert E ^a   Purohit, O P ^a   Vinholes, J J ^a   Zekri, J ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; TUMOR MARKER;

BONE METABOLISM; BONE METASTASIS; BREAST CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0030842843     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1686::aid-cncr20>3.0.co;2-v     Document Type: Conference Paper

References (18)

1. Body J-J, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996;22:265-87.
2. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
3. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and Iytic bone metastases. N Engl J Med 1996;335:1785-91.
4. Lahtinen R, Laakso M, Palva I, et al. for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340: 1049-52.
5. Conte PF, Gianessi PG, Latreille J, Mauriac L. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised multicentre phase III trial. Ann Oncol 1994;5(Suppl 7):S41-4.
6. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994;70:554-8.
7. Coleman RE, Woll PW, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with APD. Br J Cancer 1988;56:465-9.
8. Coleman RE, Vinholes J, Abbey ME, Purohit OP. Double blind randomised trial of pamidronate (Aredia) for the palliative treatment of metastatic bone disease. Proc Am Soc Clin Oncol 1996;15:528.
9. Coleman RE. Evaluation of bone disease in breast cancer. Breast 1994;3:73-8.
10. De Haes JCM, Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62:1034-9.
11. Vinholes JJ, Guo C-Y, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996;73:1089-95.
12. Vinholes JJ, Purohit OP, Abbey ME, Eastell R. Relationship between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol, in press.
13. Ernst DS, MacDonald RN, Paterson AHG, Jensen J, Bruera E. A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Sympt Manage 1992;7:4-11.
14. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289-93.
15. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993;19:79-103.
16. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Double-blind randomised trial of pamidronate for the palliative treatment of metastatic bone disease. J Clin Oncol 1997;15:131-8.
17. Robertson JFR, Pearson D, Price MR, Selby C, Blarney R, Howell A. Objective assessment of therapeutic response in breast cancer using tumour markers. Br J Cancer 1991;64: 757-63.
18. Robertson JFR. The role of serum tumour markers in breast cancer. Breast 1996;5:372-3.